Published in AIDS Weekly, July 25th, 2011
"He was treated again with ganciclovir treatment combined with foscarnet treatment but failed. Finally, he was treated with recombinant human interferon alpha-2b (IFN-alpha 2b) alone and acquired sustained inhibition to CMV. His CD4+ T-cell count increased to 186 cell/mm(3) and gained partial immune restoration," wrote Y. Wen and colleagues, Affiliated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.